Goldfinch Bio to Present at the Cowen 40th Annual Health Care Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will present at the Cowen 40^th Annual Health Care Conference. The presentation will take place on Monday, March 2, 2020, at 8:00 a.m. Eastern Time in Boston, MA.

About Goldfinch Bio

Goldfinch Bio, Inc. is a clinical stage biotechnology company that leverages a genomics-based, precision medicine approach to discovering and developing kidney disease treatments. Its Kidney Genome Atlas™ is a proprietary biology platform that drives candidate discovery, patient selection and biomarker development. The Company’s lead candidate, GFB-887, is a transient receptor potential canonical 5 (TRPC5) ion channel inhibitor being evaluated in a Phase 1 clinical trial for the treatment of kidney diseases. Goldfinch Bio is also developing GFB-024, a peripherally-restricted cannabinoid receptor 1 (CB1) monoclonal antibody, for the treatment of rare and metabolic kidney diseases and expects to submit an IND in the second half of 2020. Goldfinch Bio, headquartered in Cambridge, Massachusetts, was launched in 2016 by Third Rock Ventures and has an established strategic collaboration with Gilead Sciences, Inc. For more information about Goldfinch Bio, visit www.goldfinchbio.com.

Contacts

Goldfinch Bio:
Investors:
Argot Partners

Kimberly Minarovich / Joseph Rayne

212-600-1902

[email protected] or [email protected]

Media:
David Rosen

212-600-1902

[email protected]